series-b
Stage
1
Investors
About
Quanta Therapeutics develops allosteric small molecule inhibitors targeting KRAS mutations to treat various hard-to-treat cancers including pancreatic, colorectal, lung, and endometrial cancers by modulating RAS signaling.
Explore Quanta Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.